Targeting histone lactylation in pancreatic ductal adenocarcinoma using RNA therapeutics: from metabolic-epigenetic mechanisms to clinical translation
Pancreatic ductal adenocarcinoma (PDAC) is among the most treatment-resistant malignancies because of its dense desmoplastic stroma, metabolic plasticity, and immunosuppressive tumor microenvironment. Lactate, once viewed primarily as a glycolytic byproduct, also acts as an epigenetic signal through histone lactylation, particularly histone H3 lysine 18 lactylation (H3K18la). Recent PDAC studies implicate H3K18la in three distinct reported mechanisms: a glycolysis-H3K18la-TTK/BUB1B positive-feedback loop, an H3K18la-ACAT2-cholesterol axis that promotes macrophage-mediated immunosuppression, and a PCAF-H3K18la-CXCL1 pathway that recruits neutrophils and supports immune escape. Together, these findings identify the lactate-lactylation axis as a potential therapeutic vulnerability in PDAC. This review synthesizes evidence linking lactate metabolism, histone lactylation, immune remodeling, and therapeutic resistance, with emphasis on RNA-based interventions. We evaluate small interfering RNA, microRNA-based, antisense, and other non-coding RNA strategies directed at lactate production and transport, chromatin writers and erasers, and axis-specific effectors. We also examine translational barriers, including nuclease degradation, renal clearance, membrane impermeability, endosomal trapping, off-target effects, and limited penetration of nanoparticles through the PDAC stroma. Integrating cancer metabolism, epigenetics, immunology, and RNA nanomedicine, this review proposes a translational framework for testing lactylation-directed RNA therapeutics in PDAC.
Authors
- Muhammad Imran Sajid (ORCID: https://orcid.org/0000-0001-6502-1740)
- Muhammad Eshan
- Syeda Nazish Sohaib (ORCID: https://orcid.org/0009-0008-1473-3367)
- Emma Niskanen
- Faryal Fatima
- Kashaf Noor Babar
- Keykavous Parang
- Rakesh Kumar Tiwari
- Muhammad Mudassar Wakil
- Elena Chavez
Institutions
- University of Lahore (PK)
- Chapman University (US)
- Riphah International University (PK)
- University of Pavia (IT)
- Western University of Health Sciences (US)
Publication Details
- Journal
- Frontiers in Drug Discovery
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fddsv.2026.2004992
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00